Feline Hypokalemia and Hypokalemic Polymyopathy

Feline hypokalemia refers to a subnormal serum potassium concentration in cats, and when severe or prolonged, it results in hypokalemic polymyopathy — a neuromuscular disorder characterized by generalized muscle weakness, pain, and the pathognomonic sign of cervical ventroflexion [2]. The condition can arise from a hereditary predisposition, most notably in Burmese and related breeds, or secondary to a variety of acquired causes including dietary insufficiency, renal potassium wasting, and endocrine disorders [1][6]. Hypokalemic polymyopathy was first comprehensively described in the late 1980s and has since been recognized across Australasia, Europe, South Africa, and North America [1][2]. Because potassium is essential for normal skeletal and cardiac muscle membrane potential, even moderate deficits can produce clinically significant and potentially life-threatening muscle dysfunction.

Potassium Physiology

Potassium is the principal intracellular cation, and the ratio of intracellular to extracellular potassium concentration is the primary determinant of resting membrane potential in excitable cells. When serum potassium falls below the normal feline reference range (approximately 3.5–5.8 mEq/L), cellular membrane hyperpolarization impairs the ability of skeletal muscle fibers to depolarize and contract, resulting in weakness and, in severe cases, muscle necrosis [2].

Hereditary (Primary) Hypokalemia in Burmese Cats

A well-characterized autosomal recessive hereditary form of hypokalemic polymyopathy occurs in Burmese cats and closely related breeds [1][6]. Genome-wide association studies identified a causative variant in the WNK4 gene — making Burmese cats the first animal model of a WNK4-associated hypokalemia, a gene family also implicated in human electrolyte transport disorders [6]. WNK4 normally regulates renal tubular potassium handling; the Burmese mutation is believed to cause increased renal potassium excretion, resulting in periodic hypokalemia [6]. Onset typically occurs within the first year of life, and clinical episodes may wax and wane [1].

Secondary (Acquired) Causes

Several acquired conditions can deplete total body potassium or shift potassium intracellularly:

• ·Dietary insufficiency: Cats fed low-potassium or high-protein vegetarian diets have developed episodic hypokalemic polymyopathy, with plasma potassium significantly reduced during acute episodes [3]. The alkalinizing effect of certain diets may also increase renal potassium excretion.
• ·Primary hyperaldosteronism (Conn's syndrome): Excessive aldosterone secretion from adrenocortical adenomas or carcinomas drives renal potassium wasting and sodium retention, representing one of the most important acquired causes in middle-aged to older cats [4][5]. In a series of 13 confirmed cases, 11 of 13 cats (85%) presented with hypokalemic polymyopathy as a primary complaint [4].
• ·Chronic kidney disease (CKD): Impaired tubular potassium reabsorption and reduced dietary intake combine to produce hypokalemia; hypokalemia itself can worsen renal function, creating a vicious cycle.
• ·Gastrointestinal losses: Protracted vomiting or diarrhea depletes potassium.
• ·Iatrogenic causes: Excessive diuretic use (particularly loop diuretics) or prolonged fluid therapy with potassium-deficient solutions.
• ·Insulin administration: Insulin drives potassium into cells and can precipitate or worsen hypokalemia in diabetic cats undergoing treatment.

Pathological Mechanism in Muscle

In both hereditary and acquired forms, sustained or profound hypokalemia impairs muscle membrane repolarization and reduces muscle perfusion (vasospasm). Electromyographic studies demonstrate diffuse myopathic changes with normal motor nerve conduction velocities, confirming primary muscle dysfunction rather than a neuropathy [2]. Muscle biopsy findings range from normal on light microscopy to mild focal necrosis and regeneration on electron microscopy, suggesting that the functional deficit precedes structural damage [2].

Clinical Evaluation

A presumptive diagnosis is strongly supported by the combination of the characteristic clinical presentation — acute or episodic generalized weakness with cervical ventroflexion in a young Burmese cat, or weakness with hypertension in an older cat — together with documented hypokalemia on serum biochemistry [1][2][4].

Serum Biochemistry (Key Laboratory Indicators)

The following laboratory findings are characteristic:

Electrodiagnostics

Electromyography (EMG) reveals generalized spontaneous electrical activity (fibrillation potentials, positive sharp waves) consistent with diffuse myopathy [2]. Motor nerve conduction velocities are normal, distinguishing hypokalemic polymyopathy from peripheral neuropathy [2].

Muscle Biopsy

Histopathology may show mild myofiber necrosis and regeneration but can be unremarkable on light microscopy, especially early in the disease [2]. Electron microscopy may reveal mitochondrial and myofibrillar changes. Biopsy is more useful for ruling out other myopathies.

Imaging

• ·Abdominal ultrasound: Essential when primary hyperaldosteronism is suspected; adrenal masses (adenoma or carcinoma) are typically identifiable on ultrasound [4][5].
• ·Blood pressure measurement: Systemic hypertension (often severe, >180 mmHg systolic) is a consistent finding in primary hyperaldosteronism and should prompt further endocrine workup [4].
• ·Thoracic radiographs: Assess cardiac size in cases with suspected electrolyte-associated cardiac dysfunction.

Genetic Testing

In Burmese and related cats, a DNA test targeting the WNK4 variant is available and can identify affected homozygotes and carriers, aiding both clinical diagnosis and breeding decisions [6].

Diagnostic Response to Potassium Supplementation

Rapid clinical improvement (within 24–72 hours) following appropriate potassium supplementation supports the diagnosis and is considered part of the diagnostic workup in uncomplicated cases [1][2].

Emergency Stabilization — Severe Hypokalemia

Cats presenting with profound weakness (serum K⁺ <2.5 mEq/L) or cardiac arrhythmias require parenteral potassium supplementation:

• ·IV potassium chloride (KCl): Administered via continuous rate infusion (CRI) in isotonic fluids. The maximum safe IV infusion rate is generally ≤0.5 mEq/kg/hour to avoid fatal cardiac arrhythmias; rates should be adjusted based on the degree of depletion and ongoing losses. Electrocardiographic monitoring is advisable during aggressive IV supplementation.
• ·Avoid glucose-containing fluids, which stimulate insulin release and can worsen hypokalemia.

Oral/Subcutaneous Potassium Supplementation — Maintenance

• ·Potassium gluconate (oral): The preferred long-term supplement for cats with hereditary hypokalemia or those with chronic causes. Typical starting doses range from 2–6 mEq per cat per day, adjusted based on serial serum potassium measurements [1][2].
• ·Subcutaneous potassium supplementation: Can be useful in cats that are difficult to medicate orally; must be diluted adequately (typically ≤35 mEq/L in SC fluids) to avoid local irritation and pain.
• ·Some Burmese cats require lifelong supplementation, while others may sustain adequate serum potassium with dietary modification alone [1].

Dietary Modification

• ·Correct dietary deficiencies; ensure an appropriate commercial feline diet meeting AAFCO potassium requirements.
• ·Cats fed vegetarian or homemade diets should be transitioned to balanced commercial cat food [3].
• ·Diets with reduced acid load may help reduce renal potassium excretion.

Treatment of Primary Hyperaldosteronism

When primary hyperaldosteronism (adrenocortical tumor) is the underlying cause, two treatment strategies exist [4][5]:

Surgical (curative intent):

• ·Unilateral adrenalectomy: The treatment of choice when a discrete adrenal adenoma or unilateral carcinoma is identified. A study of 10 cats with aldosterone-secreting adrenocortical tumors reported a median survival time of 1,297 days (approximately 3.5 years) following adrenalectomy [5]. Perioperative management is critical and includes pre-surgical blood pressure control, potassium supplementation, and careful anesthetic monitoring.

Medical (palliative):

• ·Spironolactone: A mineralocorticoid receptor antagonist used to counteract the effects of excess aldosterone; reduces renal potassium wasting and helps control hypertension. Typical dose: 2–4 mg/kg/day orally.
• ·Amlodipine: Calcium channel blocker used for concurrent hypertension management; often combined with spironolactone.
• ·Ongoing oral potassium supplementation is required in medically managed cats [4].

Treatment of Concurrent Renal Disease

• ·Address underlying CKD with appropriate supportive care (hydration, phosphorus restriction, anti-hypertensive therapy as indicated).
• ·Potassium supplementation is often necessary in CKD cats with concurrent hypokalemia.

Supportive Care

• ·Nutritional support and assisted feeding may be needed in severely weak cats unable to reach food or water bowls.
• ·Physiotherapy and gentle passive range-of-motion exercises during recovery.
• ·Minimize stress; provide resting surfaces that do not require jumping.

Hereditary Burmese Hypokalemia

The prognosis for cats with hereditary hypokalemic polymyopathy is generally good to excellent with appropriate and consistent potassium supplementation [1]. Most cats respond rapidly (within 24–72 hours) to potassium correction, with strength returning to near-normal levels [2]. Although the condition is lifelong and episodes may recur — particularly if supplementation lapses — many affected cats lead normal quality lives with diligent owner management [1]. Occasional cats experience severe or refractory episodes, but mortality directly attributable to the hereditary form alone appears to be low when the condition is recognized and treated [1].

Secondary Hypokalemia

Prognosis depends heavily on the underlying etiology:

• ·Dietary cause: Excellent prognosis; hypokalemia typically resolves fully with dietary correction and temporary supplementation [3].
• ·Primary hyperaldosteronism — surgical treatment: A series of 10 surgically treated cats reported a median survival time of 1,297 days (~3.5 years) post-adrenalectomy, with some cats surviving considerably longer [5]. Cats with adrenal adenomas generally had more favorable outcomes than those with carcinomas [5].
• ·Primary hyperaldosteronism — medical management: Cats managed medically (without surgery) can achieve good quality of life but require lifelong medication; long-term survival data are more limited, and progression of the underlying adrenal tumor is a concern.
• ·CKD-associated hypokalemia: Prognosis is largely dictated by the stage and progression of the underlying renal disease; potassium supplementation can improve quality of life and may slow CKD progression.

Overall Mortality Note

Hypokalemic polymyopathy itself is rarely the direct cause of death when promptly identified and treated, but severe untreated hypokalemia can result in fatal cardiac arrhythmias. In cases with primary hyperaldosteronism, the combination of severe hypertension and adrenal malignancy significantly influences long-term outcome [4][5].

Genetic Screening (Hereditary Form)

• ·DNA testing for the WNK4 variant is available for Burmese and related breeds, enabling identification of carriers and affected cats before clinical signs develop [6]. Responsible breeding programs should screen breeding cats and avoid pairing two carriers, as the condition follows an autosomal recessive inheritance pattern.
• ·Breed registries and clubs are encouraged to incorporate genetic testing requirements to reduce prevalence of the hereditary mutation in the Burmese population [1][6].

Dietary Management

• ·Feed cats a complete and balanced commercial diet meeting AAFCO (or equivalent) nutritional standards; avoid unsupplemented home-prepared or vegetarian diets that may be potassium-deficient [3].
• ·Owners of at-risk (Burmese) cats should discuss dietary potassium content with their veterinarian.

Regular Monitoring

• ·Known-affected cats or carriers on supplementation should have serum potassium measured regularly (every 3–6 months or as directed) to ensure adequate levels are maintained and dosing adjusted as needed [1].
• ·Middle-aged to older cats (>8 years) with hypertension or hypokalemia should be screened for primary hyperaldosteronism through blood pressure measurement, plasma aldosterone concentration, and abdominal ultrasound [4].

Iatrogenic Prevention

• ·Use potassium-containing fluids (e.g., Plasmalyte, lactated Ringer's solution) for routine IV fluid therapy in cats, particularly those with pre-existing renal disease.
• ·Monitor serum potassium regularly in cats receiving diuretics, prolonged IV fluids, or insulin therapy.
• ·Ensure potassium supplementation is included in the management plan for all cats with CKD that develop hypokalemia.